Zimmer Biomet (NYSE:ZBH) Price Target Raised to $138.00 at Stifel Nicolaus

Zimmer Biomet (NYSE:ZBH) had its price target boosted by Stifel Nicolaus from $130.00 to $138.00 in a research report released on Thursday,Benzinga reports. Stifel Nicolaus currently has a buy rating on the medical equipment provider’s stock.

Several other analysts also recently weighed in on the company. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James dropped their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Royal Bank of Canada increased their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Oppenheimer cut their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Finally, BTIG Research decreased their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Price Performance

ZBH stock opened at $110.93 on Thursday. The stock has a 50-day simple moving average of $107.85 and a 200-day simple moving average of $108.07. The firm has a market cap of $22.08 billion, a P/E ratio of 21.09, a price-to-earnings-growth ratio of 1.89 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet has a 1 year low of $100.67 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.65 earnings per share. On average, equities analysts predict that Zimmer Biomet will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently made changes to their positions in the business. Dunhill Financial LLC increased its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC bought a new position in shares of Zimmer Biomet in the third quarter worth $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the third quarter valued at $31,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet during the third quarter valued at about $35,000. Finally, Quarry LP bought a new position in Zimmer Biomet in the 2nd quarter valued at about $53,000. Institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.